Jose Ricardo Soares: Genomic Testing for All Patients Considered for Clopidogrel in UK
Jose Ricardo Soares, Relief Pharmacist at Uniphar Group, reposted from University of Liverpool on LinkedIn:
”Genomic testing for all patients considered for clopidogrel (before therapy starts). UK.
Clopidogrel empirically prescribed by doctors is not working in a staggering 29% of patients – being in those ineffective in prevention of stroke or MI.
Why: being a prodrug it must be activated via CYP 2C19 — patients with loss‑of‑function these CYP variants (intermediate/poor metabolisers) get much less antiplatelet effect and more thrombotic events.
So: the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics issued a guideline that recommends CYP2C19 genotyping for all patients in whom clopidogrel is being considered, “where testing is available”.
My opinion, this means that testing will soonly be available in secondary care units across the UK.
Moreover: the PGx (pharmacogenomics) data is stored as structured data into the shared electronic health record, information readily available to the prescribers (hospital, GP/community systems).
This way it will be a once in a lifetime test.
Looks quite futuristic for a patent-expired medicine.”
Quoting University of Liverpool‘s post:
”NEWS I: New UK guideline for clopidogrel recommends pharmacogenetic testing for all patients before prescription
The UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics, led by the University of Liverpool, has published its first clinical guideline focused on the use of the antiplatelet medication clopidogrel, widely prescribed in the UK to prevent blood clots. Pharmacogenomics looks at how differences in our genes can change the way medicines affect each person.
Find out more here.”
Read the full article here.
Stay updated with Hemostasis Today.
-
May 18, 2026, 16:35Abdurrahmaan Ali Suei Elbuzidi: What is the Optimal Anticoagulation Monitoring Target in ECMO?
-
May 18, 2026, 16:34Serah N. Gathu: Gaining Valuable Updates on ACS Management at the Africa STEMI Conference
-
May 18, 2026, 16:34Mahmoud Alhariri: Apixaban in Hemodialysis-Treated Kidney Failure With Newly Diagnosed AF
-
May 18, 2026, 16:33Dimitrios Kontothanassis: The Role of Thermal Ablation in GSV Reflux Treatment – LIVE 2026
-
May 18, 2026, 16:32Michael Lichardi: New Publication on Complex Anticoagulation Management in Critical Care
-
May 18, 2026, 16:28Reza Shojaei: The Global Plasma-to-Ig Supply Chain
-
May 18, 2026, 16:01Abdul Mannan: The Hardest Conversations in Myelofibrosis
-
May 18, 2026, 15:57Bridging Innovation and Access at the WFH 2026 World Congress – South African Haemophilia Foundation
-
May 18, 2026, 15:55Pierre François Sabouret: Network Meta-Analysis of Antithrombotic Therapy in Ischemic Stroke Patients